Hosted on MSN1h
23andMe to cut 40% of workforce, end therapeutics program23andMe went public in 2021 and grew to a market valuation of $6 billion. Since April, Wojcicki had been trying to take the ...
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
Prior to that, 23andMe’s independent directors—Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery ...
LISLE, Ill., Nov. 07, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE: CTS) has declared a cash ...
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...
Genetic testing company 23andMe has appointed three new independent directors to its board, including former WeWork CFO Andre ...
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
Historian who correctly predicted 9 of last 10 presidential elections picks Harris, still Kohl’s Senior Discount: What To Know About This Money-Saving Deal Trump Media Stock Plummets in Worst Trading ...
Me has appointed three new independent directors to its board.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback